Orchestra BioMed Holdings, Inc.
OBIO
$2.64
-$0.14-5.04%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -24.23% | -25.26% | -29.19% | -33.04% | -46.16% |
| Total Depreciation and Amortization | 7.32% | 3.86% | 8.58% | 18.37% | 29.28% |
| Total Amortization of Deferred Charges | -72.32% | -97.93% | -73.10% | -47.22% | -31.29% |
| Total Other Non-Cash Items | 84.58% | 84.82% | 73.23% | 52.41% | 34.57% |
| Change in Net Operating Assets | 76.87% | 115.56% | 150.63% | 84.25% | -633.26% |
| Cash from Operations | -9.61% | -9.33% | -9.07% | -16.99% | -57.49% |
| Capital Expenditure | -270.51% | -33.33% | 61.47% | 91.19% | 86.80% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 29.87% | 158.54% | 163.36% | 156.18% | 116.94% |
| Cash from Investing | 22.48% | 158.24% | 163.01% | 155.83% | 116.67% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -99.21% | -68.31% |
| Issuance of Common Stock | 5,913.78% | 15,124.75% | -99.69% | -99.76% | -99.77% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -100.98% | -100.00% | -100.00% | -100.00% | 650.11% |
| Cash from Financing | -36.88% | -91.26% | -121.30% | -107.82% | -55.24% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -177.01% | 108.38% | 108.07% | 143.52% | 9.44% |